Market Place
News Type
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
X
Details:
IPA-001 is inhaled formulation displayed viricidal activity against SARS-CoV2 after 5 minutes contact time. It is purified extracts from a plant source. These extracts contain proteolytic enzymes that have been shown to rapidly inactivate the SARS-CoV-2 virus in vitro.
Lead Product(s): IPA-001
Therapeutic Area: Infections and Infectious Diseases Product Name: IPA-001
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Inspira
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 06, 2021
DDF Summit 2022 US
Not Confirmed
Contact SupplierDetails:
Partnership will focus on utilizing Quotient’s integrated service portfolio to support the rapid development of CytoAgents’ lead COVID-19 drug candidate, GP1681, for Phase I and II in 2020.
Lead Product(s): GP1681
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: CytoAgents
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 28, 2020
Details:
SPX-001 is a potential novel treatment, based on hypochlorous acid (HOCl), for respiratory infections and is a new drug candidate for Europe with broad-spectrum anti-pathogenic properties.
Lead Product(s): Hypochlorous Acid
Therapeutic Area: Infections and Infectious Diseases Product Name: SPX-001
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership August 03, 2022
Details:
RSV vaccine candidate (VXB-211), best-in-class efficacy as a ready-to-use fully liquid formulation,for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years of age or older.
Lead Product(s): VXB-211
Therapeutic Area: Infections and Infectious Diseases Product Name: VXB-211
Highest Development Status: Preclinical Product Type: Vaccine
Partner/Sponsor/Collaborator: Medicxi
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 21, 2022
Details:
Emergex intends to use its previously determined repertoire of Class I peptides to generate a CD8+ T cell Adaptive Vaccine as medical countermeasure for better preparedness against naturally occurring, accidental, or deliberate exposures to the bacterium that causes tularemia.
Lead Product(s): Tularemia Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 14, 2022
Details:
The agreement with ATCC is expected to enable Emergex to perform safely its studies with the wildtype Yellow Fever virus, classified as a BioSafety level 3 pathogen [BS3], to advance development of its T-Cell booster vaccine candidate.
Lead Product(s): Yellow Fever Booster Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Vaccine
Partner/Sponsor/Collaborator: ATCC
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement April 07, 2022
Details:
Bicycle identified numerous discrete families of Bicycles binding to 12 unique epitopes across all domains of the SARS-CoV-2 spike protein. These Bicycles were rapidly identified and conjugated together, creating a wide range of multi-valent and bi-paratopic molecules.
Lead Product(s): Undisclosed
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 07, 2022
Details:
Proceeds from the financing will support the clinical development and manufacturing of its lead product Neumifil. Neumifil is a unique multivalent carbohydrate binding molecule (mCBM) generated using Pneumagen’s proprietary GlycoTarge™ technology platform.
Lead Product(s): Neumifil
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Thairm Bio
Deal Size: $5.2 million Upfront Cash: Undisclosed
Deal Type: Financing January 19, 2022
Details:
ImplaVax®-enabled vaccination products leverage Enesi’s innovative unit solid-dose, thermally stable formulation and needle-free delivery technologies, and are applicable across all vaccine formats such as recombinant H7N9 pandemic influenza vaccine.
Lead Product(s): Recombinant Influenza Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Vaccine
Partner/Sponsor/Collaborator: National Institutes of Health
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement October 19, 2021
Details:
NP339 as a novel peptide therapy candidate for invasive and respiratory fungal disease. NP339 has rapid, fungicidal activity against a broad range of clinically relevant pathogens.
Lead Product(s): Np339
Therapeutic Area: Infections and Infectious Diseases Product Name: NP339
Highest Development Status: Preclinical Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 05, 2021
